Core Company Positioning • American Diversified Holdings Corporation (OTC: ADHC) is positioning itself at the intersection of healthcare technology and artificial intelligence through its flagship innovation, GlucoGuard. • ADHC is evolving from a traditional holding company into a technology-driven health solutions platform. • GlucoGuard represents its most significant value driver.
GlucoGuard Overview • GlucoGuard is designed to address nocturnal hypoglycemia. • The system combines a wearable or oral device with an AI-powered monitoring platform. • The device continuously tracks glucose levels and is designed to automatically administer glucose when levels fall below safe thresholds. • This real-time intervention capability could significantly improve patient outcomes and quality of life.
AI & Predictive Capability • The system’s algorithm has demonstrated approximately 95% accuracy in predicting hypoglycemic events. • This predictive capability transforms GlucoGuard from a passive monitoring tool into an active prevention system.
Dexcom Partnership • ADHC has a collaboration with Dexcom, a global leader in continuous glucose monitoring (CGM) technology. • GlucoGuard has gained access to Dexcom’s API. • GlucoGuard successfully completed Level 2 app integration within the Dexcom ecosystem. • It enables real-time data flow. • It validates the technology within an established healthcare infrastructure. • It increases potential adoption by leveraging Dexcom’s existing user base. • The company is positioning itself as a complementary solution that enhances the value of existing devices.
Development & Partnerships • ADHC has worked with the University of California, Irvine’s MADO program. • ADHC has engaged Arete Biosciences to support device design and development. • The company has added experienced professionals, including former FDA officials. • Partnerships are aimed at advancing software development, hardware engineering, and regulatory preparation.
FDA & Regulatory Path • ADHC filed a Breakthrough Device application with the U.S. Food and Drug Administration (FDA). • Initial feedback indicated that GlucoGuard met many of the necessary criteria. • Additional data related to safety during sleep was requested. • ADHC has initiated further studies, including a proposed sleep study. • Breakthrough Device designation could provide a faster regulatory pathway.
Financials & Valuation • ADHC secured a $5 million financing commitment in 2025. • Independent research assigned GlucoGuard an enterprise valuation of approximately $43 million. • These developments suggest growing external validation.
Market Opportunity • The U.S. diabetes market has been estimated at approximately $28 billion. • There is growing demand for continuous monitoring solutions, predictive analytics, and automated intervention systems. • GlucoGuard’s combination of AI-driven prediction and automated response aligns with these trends. ________________________________________ Broader Strategy • ADHC announced a broader initiative within its Universal Wellness AI division. • The company is aiming to build a broader ecosystem of AI-enabled wellness solutions. • GlucoGuard is serving as the foundation.
Conclusion / Investment Framing • ADHC is a speculative but intriguing player in the AI-driven healthcare space. • The company remains in a developmental stage. • Success will depend on execution, regulatory outcomes, and market adoption. • ADHC represents a high-risk, high-reward opportunity worth monitoring.
Market Data 
Markets 
AI
